Merck & Co., Inc.
NYSE
Closed
Jul 23, 2026
Day's Range
128.0152 wk Range
76.66Key Statistics
Symbol
MRK
Name
Merck & Co., Inc.
Currency
USD
Exchange
NYSE
High
131.03
Low
128.01
Open
‪128.03‬
Last
‪130.91‬
Market Cap
314.82B
Pe Ratio
‪35.60‬
Volume
483.31K
Average Volume
8.24M
Dividend Yield
‪2.63%‬
Change
3.44
Percent Change
2.70
Timestamp
2026-07-23
Close
130.91
Today Range Start
‪128.01‬
Today Range End
‪131.03‬
52 Week Range Start
‪76.66‬
52 Week Range End
‪131.74‬
Type
Stocks
Country
United States
Compliance - MRK - Merck & Co., Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-17
Business Screen
COMPLIANT
Financial Screen
NON_COMPLIANT
Compliant Revenue
‪97.00%‬
Non Compliant Revenue
‪2.00%‬
Questionable Revenue
‪1.00%‬
Securities To Market Cap Ratio
‪50.00%‬
Debt To Market Cap Ratio
‪90.00%‬
Historical Data - MRK - Merck & Co., Inc.
Historical Data
Market Cap - MRK - Merck & Co., Inc.
Market Cap
2026-07-21
311.84B
2026-07-20
307.24B
2026-07-17
314.90B
2026-07-16
315.22B
2026-07-15
305.29B
2026-07-14
298.30B
2026-07-13
306.33B
2026-07-10
305.12B
2026-07-09
308.90B
2026-07-08
311.17B
Dividend - MRK - Merck & Co., Inc.
Dividend
2026-06-15
0.8500
Splits
2021-06-03
1048-for-1000 split (0.9542)
Splits - MRK - Merck & Co., Inc.
Earnings - MRK - Merck & Co., Inc.
Earnings
Balance Sheet - MRK - Merck & Co., Inc.
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
 Assets | 136.86B | 117.10B | 106.67B | 109.16B | 105.69B | 91.58B |
| Liabilities | 84.20B | 70.73B | 69.04B | 63.10B | 67.43B | 66.18B |
| Shareholders Equity | 52.66B | 46.37B | 37.63B | 46.05B | 38.25B | 25.40B |
Cash Flow - MRK - Merck & Co., Inc.
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 14.69B | 13.31B | 6.90B | 12.77B | 8.16B | 8.15B |
| Income Tax Paid | - | - | - | - | - | - |
| Interest Paid | - | - | - | - | - | - |
| Free Cash Flow | 12.36B | 18.09B | 9.14B | 14.70B | 9.66B | 5.82B |
Income Statement - MRK - Merck & Co., Inc.
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 65.01B | 64.16B | 60.11B | 59.28B | 48.70B | 41.51B |
| Cost of Goods | 16.38B | 15.19B | 16.12B | 17.41B | 13.62B | 13.61B |
| Gross Profit | 48.62B | 48.97B | 43.98B | 41.87B | 35.07B | 27.90B |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | 22.10B | 20.22B | 2.95B | 18.28B | 13.19B | 5.54B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -26M | 571M | -284M | -1.03B | 1.45B | 1.08B |
| Pre Tax Income | 21.06B | 19.93B | 1.88B | 16.44B | 13.87B | 5.86B |
| Income Tax | 2.80B | 2.80B | 1.51B | 1.91B | 1.52B | 1.34B |
| Net Income | 18.26B | 17.13B | 377M | 14.52B | 13.06B | 7.07B |
| EPS Basic | 7.376466 | 6.771937 | 0.14 | 5.73 | 5.16 | 2.793031 |
| EPS Diluted | 7.28 | 6.74 | 0.14 | 5.71 | 5.14 | 2.78 |
| Basic Shares Outstanding | 2.47B | 2.52B | 2.60B | 2.53B | 2.53B | 2.53B |
| Diluted Shares Outstanding | 2.47B | 2.52B | 2.60B | 2.53B | 2.53B | 2.53B |
| Ebit | 22.42B | 21.20B | 3.03B | 17.40B | 14.68B | 6.69B |
| Ebitda | 29.10B | 26.22B | 7.53B | 23.30B | 16.91B | 9.56B |
| Net Income Continuous Operations | 18.26B | 17.13B | 377M | 14.52B | 12.35B | 4.52B |
| Minority Interests | -9M | -16M | -12M | -7M | -13M | -4M |
| Preferred Stock Dividends | - | - | - | - | - | - |
Recommendations - MRK - Merck & Co., Inc.
Recommendations
Profile - MRK - Merck & Co., Inc.
Profile
Mic Code
XNYS
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73K
Merck & Co., Inc. operates as a leading healthcare company worldwide, specializing in the research, development, and commercialization of innovative pharmaceutical products and vaccines. Its portfolio features prominent human health pharmaceuticals such as Keytruda for oncology treatments, Welireg for specific cancer therapies, and Gardasil for HPV prevention. The company also provides a robust lineup of vaccines including ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, and Pneumovax 23, addressing infectious diseases across age groups. Additional offerings include Bridion for surgical care. Merck & Co., Inc. focuses on key therapeutic areas like oncology, vaccines, hospital acute care, and immunology, serving patients, healthcare providers, and global health systems. Through its operations, the company plays a vital role in advancing treatments for serious diseases and preventive health measures. Founded in 1891 and headquartered in Rahway, New Jersey, Merck & Co., Inc. maintains a strong presence in the biopharmaceutical sector, contributing to global health solutions.
Profile Details
Type
Common Stock
Address
126 East Lincoln Avenue
City
Rahway
State
NJ
Zip
07065
Country
United States
Phone
908 740 4000
